Nephros (NASDAQ:NEPH) Issues Earnings Results

Nephros (NASDAQ:NEPH) posted its quarterly earnings data on Thursday. The company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01, FiscalAI reports. Nephros had a net margin of 8.26% and a return on equity of 15.81%. The firm had revenue of $4.73 million during the quarter, compared to analysts’ expectations of $4.45 million.

Here are the key takeaways from Nephros’ conference call:

• Nephros delivered 33% revenue growth to $18.8 million in 2025 and reported net income of about $1.2 million (second consecutive profitable year), finishing the year with roughly $5.4 million in cash and no debt.
• Programmatic (recurring) sales drove the business, accounting for 90%+ of revenue, while active customer sites rose to 1,681, supporting more predictable, replacement-driven revenue.
• Gross margin weakened in Q4 to 58% (from 64% year-over-year) primarily due to a tariff on imports from Italy (15% in 2025, reduced to 10% in Feb 2026), creating ongoing margin uncertainty.
• Operating costs increased—SG&A rose to $9.0 million (+17%) and R&D also grew—contributing to a Q4 adjusted EBITDA decline to $131k (down from $481k), which pressures near-term profitability despite positive full-year adjusted EBITDA of $1.6 million.
• Management is pursuing a multi-year expansion strategy anchored on products, services, and the Nephros Water Institute to penetrate non-patient commercial markets (corrections, schools, fountains, sterile processing), but wider adoption will depend on education and service-scale execution.

Nephros Trading Down 2.6%

Nephros stock traded down $0.10 during mid-day trading on Friday, hitting $3.70. The stock had a trading volume of 7,717 shares, compared to its average volume of 44,689. The stock has a 50-day simple moving average of $4.26 and a two-hundred day simple moving average of $4.64. The stock has a market capitalization of $39.33 million, a PE ratio of 28.46 and a beta of 1.42. Nephros has a 12 month low of $1.49 and a 12 month high of $6.42.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Topline Capital Management LLC boosted its stake in shares of Nephros by 13.1% in the 2nd quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock valued at $1,953,000 after purchasing an additional 55,360 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Nephros by 25.8% during the fourth quarter. Renaissance Technologies LLC now owns 103,772 shares of the company’s stock worth $506,000 after buying an additional 21,272 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Nephros by 3.2% during the second quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock worth $381,000 after buying an additional 2,898 shares during the last quarter. HighTower Advisors LLC lifted its holdings in Nephros by 7.2% in the fourth quarter. HighTower Advisors LLC now owns 59,710 shares of the company’s stock valued at $291,000 after buying an additional 4,000 shares during the period. Finally, Essex Investment Management Co. LLC boosted its stake in Nephros by 57.1% in the fourth quarter. Essex Investment Management Co. LLC now owns 38,984 shares of the company’s stock valued at $190,000 after acquiring an additional 14,162 shares during the last quarter. 41.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Nephros in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Nephros has an average rating of “Moderate Buy” and an average target price of $6.00.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.